Lisa Bright
CIK 1635111 · President, International · last filed 2020-07-06
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$0
Companies
1
Total Filings
49
Lifetime Open-Market Net
-$2.05M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted | President, International | 22,012 | $19.00 | $418.2K | -$2.05M | 43 | 2020-07-06 |
Recent Filings · Page 3 of 5
49 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-02-22 | INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted | Grant (A) | +5,500 | $0 | EDGAR |
| 2018-01-26 | INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted | Grant (A) | +2,051 | $0 | EDGAR |
| 2017-10-04 | INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted | Sell (S) | −390 | -$23.0K | EDGAR |
| 2017-08-29 | INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted | Sell (S) | −253 | -$28.2K | EDGAR |
| 2017-08-02 | INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted | Sell (S) | −142 | -$15.7K | EDGAR |
| 2017-07-05 | INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted | Sell (S) | −394 | -$47.8K | EDGAR |
| 2017-06-02 | INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted | Mixed | +767 | -$77.3K | EDGAR |
| 2017-05-30 | INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted | Sell (S) | −254 | -$29.9K | EDGAR |
| 2017-05-18 | INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted | Mixed | +122 | -$13.5K | EDGAR |
| 2017-05-10 | INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted | Mixed | +453 | -$48.6K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.